Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Ophthalmic Drug Delivery Systems

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

Glaucoma: Overview

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...

Drug Delivery: Miscellaneous Routes

Drug Delivery: Miscellaneous Routes

Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...

Oral Drug Delivery Systems: Continuous-Release Systems

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Global, regional, and national burden of clavicle, scapula, or humerus fracture in 204 countries and territories, 1990 to 2021: A systematic analysis from the Global Burden of Disease Study 2021.

Medicine·2026

Same author

Discovery of potent and highly selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for treating diabetic nephropathy.

Frontiers in pharmacology·2026

Same author

Deciphering the interplay between fruit-associated metabolites and bacterial communities across four distinct mango cultivars.

Frontiers in plant science·2026

Same author

Ultrafast solvent removal delivers high-loading of amorphous small-molecule drugs in polymeric microspheres with predictable in vivo performance.

Journal of controlled release : official journal of the Controlled Release Society·2026

Same author

Bioinspired Fe Single-Atom Nanozyme Synergizes with Natural NarGH Dimer for High-Efficiency Photobiocatalytic Nitrate Conversion.

Journal of the American Chemical Society·2025

Same author

Programmable Nanostructure Assembly of a Paclitaxel Derivative Enables Tunable Anticancer Therapy via Hydrogen Bond Engineering.

ACS nano·2025

Search research articles

Related Experiment Video

Updated: Jun 6, 2026

Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications

Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications

Published on: November 17, 2015

A potential new therapeutic system for glaucoma: solid lipid nanoparticles containing methazolamide.

Rui Li¹, Sunmin Jiang, Dongfei Liu

¹School of Pharmacy, Nanjing Medical University, 140 Hanzhong Road, Nanjing 210029, People's Republic of China.

Journal of Microencapsulation

|December 15, 2010

Summary

This study developed methazolamide (MTA)-loaded solid lipid nanoparticles (SLNs) for glaucoma treatment. MTA-SLNs demonstrated enhanced therapeutic efficacy and prolonged action compared to conventional treatments, offering a promising ocular drug delivery system.

More Related Videos

Experimental Glaucoma Induced by Ocular Injection of Magnetic Microspheres

Experimental Glaucoma Induced by Ocular Injection of Magnetic Microspheres

Published on: February 2, 2015

Related Experiment Videos

Last Updated: Jun 6, 2026

Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications

Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications

Published on: November 17, 2015

Experimental Glaucoma Induced by Ocular Injection of Magnetic Microspheres

Experimental Glaucoma Induced by Ocular Injection of Magnetic Microspheres

Published on: February 2, 2015

Area of Science:

Ophthalmology
Nanotechnology
Pharmaceutics

Background:

Systemic administration of methazolamide (MTA) for glaucoma presents challenges, including side effects and inadequate ocular concentrations.
Current treatments may not provide optimal therapeutic levels within the eye.

Purpose of the Study:

To formulate methazolamide-loaded solid lipid nanoparticles (MTA-SLNs).
To evaluate MTA-SLNs as a novel therapeutic system for glaucoma.
To assess the physicochemical properties, pharmacodynamics, and ocular irritation of MTA-SLNs.

Main Methods:

MTA-SLNs were prepared using a modified emulsion-solvent evaporation technique.
Physicochemical characteristics, pharmacodynamic effects (intraocular pressure reduction), and ocular irritation (Draize test) were evaluated.

Main Results:

MTA-SLNs exhibited a burst release but demonstrated superior therapeutic efficacy compared to drug solution and commercial products.
The nanoparticles showed a later onset of maximum action and a more prolonged therapeutic effect.
Ocular irritation studies were conducted to assess safety.

Conclusions:

MTA-SLNs represent a potential ocular drug delivery carrier for glaucoma.
This formulation offers advantages such as intensive treatment, reduced dosage, and improved patient compliance over conventional eye drops.